FSD Pharma Makes Progress with MS Study

In preclinical models, Lucid-MS has been shown to prevent a hallmark pathology feature of MS.

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) completed dosing the first cohort of patients in the company’s Phase I clinical trial of Lucid-21-302 (Lucid-MS).

The clinical trial (ClinicalTrials.gov identifier: NCT05821387), which is being conducted by FSD Pharma through the company’s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a small molecule inhibitor of hyper citrullination, as a novel drug candidate for the treatment of multiple sclerosis. Today, there is no cure for MS.

“Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals. “The safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled to say is expected to commence in the next few days.”

MS is known for its unpredictable symptoms, such as tingling sensations, vision problems, and mobility issues, that are attributed to the patient’s immune system attacking different nerve fibers. The global MS treatment market in 2022 is estimated at $23 billion.

MS can occur at any age, but the average age for diagnosis globally is 32 years. Just 1.5% of the global MS population is under the age of 18 years, and the female-to-male diagnosis ratio is 2:1.

Study Details

The Lucis-MS clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study with the primary outcomes evaluating the safety, tolerability, and pharmacokinetics in healthy volunteers under fed and fasted conditions.

Enrollment will be comprised of five SAD cohorts and two MAD cohorts. Each SAD and MAD cohort will enroll eight participants (for a total of 56 participants), randomized to six active and two placebo groups. Participants in the active group will receive single or multiple doses of Lucid-MS. For the SAD cohort with food effect, all eight participants will receive Lucid-MS.

In preclinical models, Lucid-MS has been shown to prevent myelin degradation (demyelination), a hallmark pathology feature of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system.

Preclinical evidence demonstrated Lucid-MS promotes functional recovery in experimental animal models of MS. Based on current evidence, Lucid-MS is a nonimmunomodulatory agent, an important distinction in the potential for developing new, safe options for treating MS.

The company expects to launch the Phase 2 trial in 2024. FSD also has a psilocybin-based compound drug that it is developing for major depressive disorder.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Back to Top

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.